Identification of a new scaffold for Hsp90 C-terminal inhibition

ACS Medicinal Chemistry Letters

Volumn 5, Issue 1, 2014, Pages 84-88

  Zhao, Huiping ^a   Moroni, Elisabetta ^b   Colombo, Giorgio ^b   Blagg, Brian S J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b CNR   (Italy)

Author keywords

biphenyl; breast cancer; Heat shock protein 90; Hsp90 C terminal inhibitors; novobiocin

Indexed keywords

BIPHENYL; COUMARIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NOVOBIOCIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 84892581772     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400404s     Document Type: Article

References (26)

1. Taipale, M.; Jarosz, D. F.; Lindquist, S. Hsp90 at the hub of protein homeostasis: Emerging mechanistic insights Nat. Rev. Mol. Cell Biol. 2010, 11, 515-528
2. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: The next generation Cell 2011, 144, 646-674
3. Blagg, B. S. J.; Kerr, T. D. Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation Med. Res. Rev. 2006, 26, 310-338
4. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res. 2012, 1, 64-76
5. Whitesell, L.; Santagata, S.; Lin, N. U. Inhibiting Hsp90 to treat cancer: A strategy in evolution Curr. Mol. Med. 2012, 12, 1108-1124
6. Marcu, M. G.; Schulte, T. W.; Neckers, L. M. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins J. Natl. Cancer Inst. 2000, 92, 242-248
7. Eskew, J. D.; Sadikot, T.; Morales, P.; Duren, A.; Dunwiddie, I.; Swink, M.; Zhang, X. Y.; Hembruff, S.; Donnelly, A.; Rajewski, R. A.; Blagg, B. S. J.; Manjarrez, J. R.; Matts, R. L.; Holzbeierlein, J. M.; Vielhauer, G. A. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells BMC Cancer 2011, 11, 468
8. Shelton, S. N.; Shawgo, M. E.; Comer, S. B.; Lu, Y.; Donnelly, A. C.; Szabla, K.; Tanol, M.; Vielhauer, G. A.; Rajewski, R. A.; Matts, R. L.; Blagg, B. S.; Robertson, J. D. KU135, a novel novobiocin-derived C-terminal inhibitor of Hsp90, exerts potent antiproliferative effects in human leukemic cells Mol. Pharmacol. 2009, 76, 1314-1322
9. Conde, R.; Belak, Z. R.; Nair, M.; O'Carroll, R. F.; Ovsenek, N. Modulation of Hsf1 activity by novobiocin and geldanamycin Biochem. Cell Biol. 2009, 87, 845-851
10. Zhao, H. P.; Donnelly, A. C.; Kusuma, B. R.; Brandt, G. E. L.; Brown, D.; Rajewski, R. A.; Vielhauer, G.; Holzbeierlein, J.; Cohen, M. S.; Blagg, B. S. J. Engineering an antibiotic to fight cancer: Optimization of the novobiocin scaffold to produce anti-proliferative agents J. Med. Chem. 2011, 54, 3839-3853
11. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin: Redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90 J. Am. Chem. Soc. 2006, 128, 15529-15536
12. Zhao, H. P.; Kusuma, B. R.; Blagg, B. S. J. Synthesis and evaluation of noviose replacements on novobiocin that manifest antiproliferative activity ACS Med. Chem. Lett. 2010, 1, 311-315
13. Donnelly, A. C.; Zhao, H. P.; Kusuma, B. R.; Blagg, B. S. J. Cytotoxic sugar analogues of an optimized novobiocin scaffold Med. Chem. Commun. 2010, 1, 165-170
14. Le Bras, G.; Radanyi, C.; Peyrat, J. F.; Brion, J. D.; Alami, M.; Marsaud, V.; Stella, B.; Renoir, J. M. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90 J. Med. Chem. 2007, 50, 6189
15. Audisio, D.; Messaoudi, S.; Cegielkowski, L.; Peyrat, J. F.; Brion, J. D.; Methy-Gonnot, D.; Radanyi, C.; Renoir, J. M.; Alami, M. Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery ChemMedChem 2011, 6, 804
16. Donnelly, A. C.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B. S. J. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity J. Org. Chem. 2008, 73, 8901-8920
17. Welsch, M. E.; Snyder, S. A.; Stockwell, B. R. Privileged scaffolds for library design and drug discovery Curr. Opin. Chem. Biol. 2010, 14, 1-15
18. Horton, D. A.; Bourne, G. T.; Smythe, M. L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures Chem. Rev. 2003, 103, 893-930
19. Turrado, C.; Puig, T.; Garcia-Carceles, J.; Artola, M.; Benhamu, B.; Ortega-Gutierrez, S.; Relat, J.; Oliveras, G.; Blancafort, A.; Haro, D.; Marrero, P. F.; Colomer, R.; Lopez-Rodriguez, M. L. New synthetic inhibitors of fatty acid synthase with anticancer activity J. Med. Chem. 2012, 55, 5013-5023
20. Matts, R. L.; Dixit, A.; Peterson, L. B.; Sun, L.; Voruganti, S.; Kalyanaraman, P.; Hartson, S. D.; Verkhivker, G. M.; Blagg, B. S. J. Elucidation of the Hsp90 C-terminal inhibitor binding site ACS Chem. Biol. 2011, 6, 800-807
21. Morra, G.; Neves, M. A. C.; Plescia, C. J.; Tsustsumi, S.; Neckers, L.; Verkhivker, G.; Altieri, D. C.; Colombo, G. Dynamics-based discovery of allosteric inhibitors: Selection of new ligands for the C-terminal domain of Hsp90 J. Chem. Theory Comput. 2010, 6, 2978-2989
22. Zhao, H. P.; Moroni, E.; Yan, B.; Colombo, G.; Blagg, B. S. J. 3D-QSAR assisted design, synthesis and evaluation of novobiocin analogue ACS Med. Chem. Lett. 2013, 4, 57-62
23. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S. J. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines J. Org. Chem. 2008, 73, 2130
24. Zhao, H. P.; Brandt, G. E.; Galam, L.; Matts, R. L.; Blagg, B. S. J. Identification and initial SAR of silybin: An Hsp90 inhibitor Bioorg. Med. Chem. Lett. 2011, 21, 2659-2664
25. Zhao, H. P.; Yan, B.; Peterson, L. B.; Blagg, B. S. J. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition ACS Med. Chem. Lett. 2012, 3, 327-331
26. Tran, P.; Kim, S. A.; Choi, H. S.; Yoon, J. H.; Ahn, S. G. Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo BMC Cancer 2010, 10, 276